8-K: Sensei Biotherapeutics Announces Promising Clinical Data for SNS-101 Phase 1 Study

Sensei Biotherapeutics reported encouraging initial clinical data from its Phase 1/2 trial of SNS-101, showing potential in treating advanced solid tumors.

Summary

• Sensei Biotherapeutics has released positive preliminary data from the dose escalation phase of its Phase 1/2 clinical trial for SNS-101, a conditionally active antibody targeting VISTA.
• The study included 34 patients with advanced solid tumors, with 16 receiving SNS-101 monotherapy and 18 receiving it in combination with Regeneron's Libtayo.
• The majority of patients (85%) had tumors typically unresponsive to PD-1 monotherapy.
• Data as of April 30, 2024, showed promising clinical activity, including a confirmed partial response in one endometrial cancer patient and tumor regression in colorectal and renal cell cancer patients.
• SNS-101 demonstrated a favorable pharmacokinetic profile, supporting once every three-week dosing, and was well-tolerated with mostly mild adverse events.
• The company plans to present the data at the ASCO Annual Meeting on June 1, 2024, and hold an investor webcast on June 3, 2024.

Sentiment

Score: 8

Explanation: The document presents positive clinical data with a focus on the potential of SNS-101, suggesting a strong positive sentiment. The safety profile is also encouraging, further boosting the positive outlook.

Positives

• SNS-101 has shown encouraging clinical activity in multiple tumor types, including those typically resistant to PD-1 inhibitors.
• The drug has a favorable safety profile with no dose-limiting toxicities and mostly mild adverse events.
• The pharmacokinetic profile supports convenient once every three-week dosing.
• The data suggests that SNS-101 may overcome previous challenges associated with VISTA-targeted therapies.
• The study showed dose-dependent changes in specific T-cell populations, suggesting a pharmacological effect.

Negatives

• Two patients experienced mild Grade 1 cytokine release syndrome (CRS).
• Four patients in the combination cohort experienced immune-mediated events.

Risks

• The study is still in its early phases, and further trials are needed to confirm the efficacy and safety of SNS-101.
• There are risks associated with the development of therapeutic product candidates, including the possibility of delays or cessation of clinical trials.
• The company is dependent on third-party suppliers and manufacturers, which could pose risks.
• There are risks regarding the accuracy of the company's estimates of expenses, capital requirements, and needs for additional financing.

Future Outlook

The company expects to report initial data from the dose expansion cohorts and to hold an end-of-Phase 1 meeting with the FDA by the end of 2024.

Management Comments

• Dr. Shiraj Sen stated that SNS-101 has been well-tolerated and shows potential to overcome prior challenges of VISTA-targeted programs.
• Ron Weitzman, Chief Medical Officer of Sensei Bio, believes the data validates the mechanism of action and shows a potentially best-in-class PK and safety profile.

Industry Context

The development of SNS-101 addresses the need for new therapies for patients with advanced solid tumors, particularly those resistant to current immunotherapy treatments. The focus on VISTA as a target is part of a broader trend in immuno-oncology to explore novel immune checkpoints.

Comparison to Industry Standards

• The reported partial response in an MSS endometrial cancer patient is notable, as this type of cancer has historically shown low response rates to immunotherapy.
• The tumor regression observed in MSS colorectal cancer and pembrolizumab-resistant renal cell carcinoma patients is also significant, as these cancers are often unresponsive to PD-1 treatments.
• The favorable pharmacokinetic profile of SNS-101, with linear elimination kinetics and dose-proportional increases in exposure, is a positive differentiator compared to non-conditionally active anti-VISTA antibodies that have shown target-mediated drug disposition.
• The well-tolerated safety profile of SNS-101, with no dose-limiting toxicities and mostly mild adverse events, is a key advantage over previous VISTA-targeting approaches that have faced safety issues.

Stakeholder Impact

• Shareholders may react positively to the promising clinical data.
• Employees may be encouraged by the progress of the company's lead candidate.
• Patients with advanced solid tumors may benefit from the development of new treatment options.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• Patient enrollment is advancing in the dose expansion portion of the Phase 1/2 study.
• The company expects to report initial data from the dose expansion cohorts by the end of 2024.
• The company plans to hold an end-of-Phase 1 meeting with the FDA by the end of 2024.
• The data will be presented at the ASCO Annual Meeting on June 1, 2024.
• Sensei will host an investor webcast on June 3, 2024, to discuss the data.

Key Dates

Keywords

SNS-101, VISTA, Immuno-oncology, Monoclonal Antibody, Cancer Therapy, Clinical Trial, Tumor Microenvironment, PD-1 Inhibitor, Cemiplimab, Solid Tumors